The data on this is limited for retatrutide since it is newer, but the general pattern with GLP-1 agonists suggests that maintaining weight loss after stopping requires lifestyle modifications regardless of which compound you used
Hesse S, van de Giessen E, Zientek F, Petroff D, Winter K, Dickson JC, et al
Comorbidities such as cardiovascular disease, sleep apnea, or uncontrolled diabetes change priorities: reduce hypoglycemia risk, avoid volume depletion, and maintain glycemic targets that fit the procedures risk profile
Recent studies have shown mixed results regarding semaglutide and liver damage
Initiating GLP-1 therapy requires careful patient selection and thorough counseling about realistic expectations
Oral semaglutide may be preferred by those looking to avoid needles, while injectable semaglutide offers stronger results and a more flexible dosing schedule